Woo Young Medical has been a medical device manufacturer specialized in research, development, production and sale of Elastomeric Infusion Pump and Electronic Infusion Pump. By contributing health and happiness to humanity, realizing the individual values of life, and fulfilling social responsibilities, Woo Young Medical strives for constant quality improvement and adapts to the changing market environment to become an advanced enterprise.
Wales Cymru (Welsh Government)
Wales is a self-governing country of the UK and the Welsh Government is the devolved Government for Wales. The Welsh Government’s decision-making powers within a small and joined-up country mean we can act fast. They also mean we are responsible for our own economic development, so you won’t find a more pro-business Government anywhere. Wales has a strong industrial heritage that has shaped our confident, creative and ambitious economy of today. Wales means business.
Vacino Biotech Co., Ltd.
Vacino Biotech focuses on innovations for HLA-peptide based vaccine (9-mer peptide), nucleic acid medicine (microRNA) and brain delivery technology (targeting peptide) for the indication of infectious disease, neurodegenerative disease and oncology. Core products: Oral universal COVID vaccine against SARS-CoV-2 variants A microRNA-based anti-neuroinflammation therapeutics A brain shuttled anti-Her2 antibody for treating the peripheral and intracranial tumors. An oral bioavailable brain-targeting LNP for delivering the oligonucleotide and large molecule therapeutics Show less Description (NOTE: Given time constraints & strategic priorities, we will not be meeting with CMOs, CROs, service companies, etc. at the meeting) Founded in July 2020, Vacino Biotech is committed to the development of novel nucleic acid drugs and universal vaccines. With the self-developed next-generation vaccine design SED technology, we have invested in the development of COVID-19 T-cell vaccine products to solve the situation of rapid mutation of the new coronavirus variants. In addition, it has invested in the development of nucleic acid drugs for the treatment of Alzheimer’s disease and a cutting-edge efficient brain delivery technology to increase the content of brain treatment drugs and prevent the occurrence of diseases at an early stage. ● Core products and platform technology Oral universal COVID-19 vaccine: VACINO-CO is a novel oral universal antigen vaccine designed to protect against most COVID-19 viruses and related variants. Through the activation of T cells, it can eliminate virus-infected cells, which can effectively inhibit recurrence and the phenomenon of seroconversion. The innovative and convenient oral dosage form can be applied to the elderly and children in vulnerable groups to obtain safer and effective immunity, safe and effective immune protection of the population. It is currently about to enter human clinical trials. MicroRNA-based Alzheimer’s Disease Drug Developments: Patented Vacino-ADmir is a microRNA-based drug that inhibits neuroinflammation through the PD1/PDL1 mechanism associated with inflammation and can be treated from the source of the disease, which is different from the symptomatic treatment on the market. It can be applied to dementia and neuroinflammation-related diseases. GMP manufacturing is currently underway. High-Performance Brain Delivery Platform Technology: The patented Vacino-BT target peptide can be co-transported by binding to transferrin receptors through transcytosis, with a brain delivery rate of more than 20 % a 1-hour post-injection, which is far superior to other brain delivery technologies on the market. At present, it has been successfully applied to antibodies and lipid nanoparticles. GoBrain LNP: Based VBT technology, we developed VBT-lipid conjugates that can enable LNP having brain targeting capability. HerBrain and eHerbrain platform: Based on VBT technology, we developed chemically modified anti-Her2 antibody and novel DNA-engineered anti-Her2 antibody, which allows brain shuttle capability and tissue penetration.
TAHO Pharmaceuticals
AHO is a commercial-stage specialty pharma pioneering in oral, transdermal drug delivery systems. Collaborating with our partners across three continents, our pipeline of medicines targets CNS, Geriatric, and Pediatric therapies that provide caregivers with significant treatment options. From concept to commercial, we have several products launched in major markets. Trusted by partner pharma, we devote toward partner value and innovation. | TAHO Pharmaceuticals, founded in 2010 in Taipei, Taiwan, and listed on the Taipei Exchange, is dedicated to transforming drug delivery with heart and innovation. We specialize in advanced formulations that make oral and injectable medications safer, more effective, and easier to use. Our mission is to enhance patient lives with thoughtful, next-generation solutions for diverse needs, especially those struggling with traditional treatments. Our success stems from our proprietary Transepithelial Delivery System (TDS) platform. It features: Transdermal Delivery: Patches provide steady medication through the skin, eliminating injections or frequent dosing—ideal for chronic care. Transmucosal Delivery: Oral thin films ensure rapid onset, enhanced bioavailability, and improved experience via the mucosa. We’re not merely creating new delivery methods—we are redefining the future of healthcare with compassion, ensuring our innovations bring hope and comfort to patients and caregivers. | TAHO Pharmaceuticals Ltd., founded in 2010 and headquartered in Taipei, Taiwan, is a publicly listed company on the Taipei Exchange. The company focuses on advancing drug delivery through innovative formulation technologies that improve the safety, efficacy, and convenience of existing medications. Leveraging its proprietary Transepithelial Delivery System (TDS) platform, TAHO develops transdermal and transmucosal drug delivery solutions designed to enable efficient drug absorption, improve patient compliance, and optimize therapeutic outcomes. By creating patient-friendly alternatives to traditional oral and injectable medications, TAHO is committed to addressing unmet medical needs and improving quality of life for patients worldwide. | TAHO is an R&D-driven specialty pharma pioneering oral and transdermal drug-delivery systems. TAHO’s Transepithelial Delivery System enables the development of oral dissolving films and transdermal patches for anticoagulants and many other treatments
Sussex Research Laboratories Inc.
Sussex Research Laboratories Inc. (Ottawa, Canada) is a globally recognized specialist in empowering therapeutic innovation through glycoscience. The company applies its expertise in glycodesign, glycan and glycoconjugate synthesis, and linker chemistries across a wide range of therapeutic areas, including vaccine development, protein and antibody engineering, and targeted drug delivery. With 30 years of experience as a Contract Research & Development (CRO) service provider, Sussex Research supports pharmaceutical and biopharmaceutical partners in applying glycotechnology to next-generation therapeutics, including oligonucleotide, peptide, protein, lipid, and small-molecule modalities, as well as lipid nanoparticle (LNP) technologies for modern drug design and delivery. The company is also widely recognized for its enabling product portfolio of advanced glycans, glycopeptides, glycoconjugates, and targeting ligand/linker systems.
Pyramid Labs
SFF CDMO Aseptic Fill/Finish Services. Vial and Syringe Filling Lyophilization Analytical Services In-house Bioburden & Sterility Clinical & Commercial Manufacturing Stability Services Clinical & Commercial Labeling Breakloose/Glide Force testing. PPQ High Recovery Vials HRV US based manufacturing sites Drug Product CMC 510k Biologics mAb oligonucleotides peptides small molecules siRna nanoparticles Parenteral filling | Pyramid Pharma Services is a U.S.-based clinical-to-commercial fill-finish CDMO with over 26 years of GMP drug product manufacturing experience and more than 35 years in business. We provide aseptic manufacturing and sterile manufacturing solutions for complex injectable drug products, supporting both emerging biotech and established pharmaceutical companies. Our expertise includes oligonucleotides, peptides, biologics, and advanced therapeutics, with integrated capabilities that span formulation development, aseptic fill-finish, lyophilization, prefilled syringe and cartridge filling, device assembly, labeling, packaging, and analytical services. By offering end-to-end drug product manufacturing within a single organization, we reduce complexity, accelerate timelines, and ensure consistent execution from clinical development through commercial supply. Pyramid’s California-based facilities support flexible manufacturing across a range of batch sizes and delivery formats, including vials, prefilled syringes, and cartridges. Ongoing investment in advanced, high-speed fill-finish infrastructure strengthens our ability to deliver scalable, reliable solutions for increasingly complex injectable therapies. Our track record includes over 100 successful IND-enabling programs, multiple commercial products, and a strong history of FDA inspections—demonstrating a consistent focus on quality, compliance, and execution. As a fill-finish CDMO, we partner closely with our clients’ CMC, technical, and regulatory teams to support efficient development and commercialization. We work with companies developing injectable therapies that require a reliable, experienced partner for sterile fill-finish and aseptic drug product manufacturing. If you are advancing a program and evaluating a CDMO for fill-finish or drug product manufacturing, we welcome the opportunity to connect at BIO 2026. Schedule time with our team to discuss your program.
ProJect Pharmaceutics (PJP)
PJP is the go-to specialist in formulation and process development across complex biologics, bioconjugates, and other therapeutic modalities. Our development agility spans liquid, frozen, and lyo formats in vials, cartridges, or pre-filled syringes and in-step or independent from your chosen manufacturer. Let’s solve your formulation and process challenges together.
PreciGenome LLC
PreciGenome LLC, located in the heart of Silicon Valley in San Jose, California, is a leading innovator in developing state-of-the-art Lipid Nanoparticle (LNP) synthesis instruments and associated reagents, empowering researchers and pharmaceutical developers in their drug delivery endeavors. Our advanced microfluidic platforms enable precise and efficient LNP production, crucial for mRNA therapeutics and vaccine development. We offer comprehensive solutions that include both cutting-edge instrumentation, high-quality reagents and services, ensuring seamless integration and optimal results for our clients. At PreciGenome, we understand the critical nature of LNP formulation in modern drug delivery systems. Our technology delivers consistent particle size distribution and exceptional encapsulation efficiency, meeting the exacting standards required in pharmaceutical development. Whether you’re conducting early-stage research or scaling up for production, our systems provide the reliability and reproducibility essential for success in LNP-based therapeutics.
PDR Design
For 30 years, PDR has been creating distinct, successful and award-winning products for innovative companies ranging from start-ups to blue chips across the world. Ranked as the #1 Design Agency in the UK for Medical Device design and in the top five in the US and Europe by the two leading global design ranking organisations. PDR has made hundreds of products covering everything from consumer goods to complex, life-critical medical devices from discovery and pipeline mapping through conception to successful market launch and beyond. Trusted by many of the world’s leading brands, PDR prides itself on repeatedly developing solutions that truly connect to users and challenge markets. Solutions which are consistently completed to budget, to target and on time. Services: • Medical Device Design • Human Factors and Usability Engineering • GUI Design • User Centred Design • Product Design • Industrial Design • Service Design • Consumer Insight Research • New Opportunity Identification and Execution